Jan 13, 2025
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Dec 19, 2024
TRYNGOLZA(TM) (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
Nov 06, 2024
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Nov 04, 2024
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Oct 23, 2024
Ionis to hold third quarter 2024 financial results webcast
Oct 01, 2024
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Jul 31, 2024
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx(TM) System for Administration of nusinersen
Jul 22, 2024
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Jul 18, 2024
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
Jun 25, 2024
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Jun 18, 2024
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Jun 17, 2024
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
May 28, 2024
Ionis to hold donidalorsen Phase 3 data webcast
May 23, 2024
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA(TM) (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
May 16, 2024
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 07, 2024
Ionis reports first quarter 2024 financial results
Apr 25, 2024
Ionis Publishes 2023 Corporate Responsibility Report
Apr 23, 2024
Ionis to hold first quarter 2024 financial results webcast
Apr 01, 2024
Ionis to present at upcoming investor conferences